In liver, prostate, pancreatic, and breast cancer, NO mechanisms have been identified at cGMP-related levels [32] These mechanisms involve a cGMP pathway that triggers ERK phosphorylation, subsequently activating TACE (ADAM17) to elevate NOTCH and EGF. Here, ADAM17 is linked to breast cancer.